Butanediamide,N4-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N1-(5-aminopentyl)-N1-hydroxy- cas no:70-51-9
Synonyms: Butanediamide,N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-(9CI); Propionohydroxamic acid,N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-(8CI); 3,9,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone,30-amino-3,14,25-trihydroxy-; 30-Amino-3,14,25-trihydroxy-3,9,14,20,25pentaazatriacontane-2,10,13,21,24-pentaone; Deferoxamin; Deferoxamine;Deferoxamine B; Deferriferrioxamine B; Deferrioxamine; Deferrioxamine B;Desferan; Desferex; Desferin; Desferioxamine B; Desferrin; Desferrioxamine;Desferrioxamine B;N-[5-[3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]propionohydroxamicacid; NSC 527604
NameButanediamide,N4-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N1-(5-aminopentyl)-N1-hydroxy-
CAS70-51-9
SynonymsButanediamide,N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-(9CI); Propionohydroxamic acid,N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-(8CI); 3,9,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone,30-amino-3,14,25-trihydroxy-; 30-Amino-3,14,25-trihydroxy-3,9,14,20,25pentaazatriacontane-2,10,13,21,24-pentaone; Deferoxamin; Deferoxamine;Deferoxamine B; Deferriferrioxamine B; Deferrioxamine; Deferrioxamine B;Desferan; Desferex; Desferin; Desferioxamine B; Desferrin; Desferrioxamine;Desferrioxamine B;N-[5-[3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]propionohydroxamicacid; NSC 527604
EINECS(EC#)200-738-5
Molecular FormulaC25H48 N6 O8
Molecular Weight560.68
refractive index1.537
Safety
Poison by intravenous route. Moderately toxic by ingestion, intraperitoneal and subcutaneous routes. Human systemic effects: changes in hearing acuity, eye hemorrhage, optic nerve neuropathy, thrombocytopenia, visual field changes. Human mutation data reported. When heated to decomposition it emits toxic fumes of NOx.
| Organism |
Test Type |
Route |
Reported Dose (Normalized Dose) |
Effect |
Source |
| child |
TDLo |
multiple routes |
440mg/kg/6D-I (440mg/kg) |
SENSE ORGANS AND SPECIAL SENSES: "RETINAL CHANGES (PIGMENTARY DEPOSITIONS, RETINITIS, OTHER): EYE" |
Archives of Disease in Childhood. Vol. 63, Pg. 250, 1988. |
| child |
TDLo |
subcutaneous |
12gm/kg/17W-I (12000mg/kg) |
SENSE ORGANS AND SPECIAL SENSES: OPTIC NERVE NEUROPATHY: EYE
SENSE ORGANS AND SPECIAL SENSES: CHANGE IN ACUITY: EAR |
New England Journal of Medicine. Vol. 314, Pg. 869, 1986. |
| human |
TDLo |
subcutaneous |
37gm/kg/2Y-I (37000mg/kg) |
SENSE ORGANS AND SPECIAL SENSES: OPTIC NERVE NEUROPATHY: EYE |
New England Journal of Medicine. Vol. 314, Pg. 869, 1986. |
| man |
TDLo |
intravenous |
86mg/kg/1H-C (86mg/kg) |
BLOOD: THROMBOCYTOPENIA |
American Journal of Kidney Diseases. Vol. 6, Pg. 254, 1985. |
| mouse |
LD50 |
intraperitoneal |
1680mg/kg (1680mg/kg) |
|
Kiso to Rinsho. Clinical Report. Vol. 4, Pg. 99, 1970. |
| mouse |
LD50 |
intravenous |
250mg/kg (250mg/kg) |
LUNGS, THORAX, OR RESPIRATION: DYSPNEA |
United States Patent Document. Vol. #4863964, |
| mouse |
LD50 |
oral |
1340mg/kg (1340mg/kg) |
|
Arzneimittel-Forschung. Drug Research. Vol. 17, Pg. 748, 1967. |
| mouse |
LD50 |
subcutaneous |
1450mg/kg (1450mg/kg) |
|
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 6, Pg. 119, 1975. |
| rat |
LD50 |
intravenous |
329mg/kg (329mg/kg) |
|
Toxicology and Applied Pharmacology. Vol. 18, Pg. 185, 1971. |
| rat |
LD50 |
subcutaneous |
12240mg/kg (12240mg/kg) |
|
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 6, Pg. 119, 1975. |
| women |
TDLo |
intravenous |
40mg/kg (40mg/kg) |
SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE
SENSE ORGANS AND SPECIAL SENSES: HEMORRHAGE: EYE |
Nephron. Vol. 46, Pg. 211, 1987.
|
